Report : Europe Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)
Gastrointestinal Cancer Segment to Dominate Europe Neoantigens Market during 2023–2028
According to a new market research study on “Europe Neoantigens Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Treatment and Therapeutic Specialty,” is expected to reach US$ 341,855.35 thousand by 2028 from US$ 86,165.00 thousand in 2023. The market is estimated to grow at a CAGR of 31.7% from 2023 to 2028. The report provides trends prevailing in the Europe neoantigens market along with the drivers and restraints pertaining to the market growth. Evolution in neoantigen vaccines against cancer is the major factor driving the growth of the Europe neoantigens market. However, possible side effects associated with neoantigen vaccines may hinder the growth of Europe neoantigens market.
In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.
The market for neoantigens market is segmented into treatment, therapeutic specialty, and country. Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on therapeutic specialty, the market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market. Based on country, the market is segmented into Germany, UK, France, Italy, Spain, and rest of Europe. In 2023, Germany is estimated to have the largest share of the market
Achilles Therapeutics plc, Frame Cancer Therapeutics, Genocea, Immunicum AB, Medigene AG, and Moderna, Inc are among the leading companies in the Europe neoantigens market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Achilles Therapeutics gets European Patent Office (“EPO”) to grant European patent EP3288581B which covers the treatment of cancer using T cells that have been selectively expanded to target clonal neoantigens.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org